Abstract-The purpose of this study was to determine if ambulatory blood pressure measurement predicted total and cardiovascular mortality over and beyond clinic blood pressure measurement and other cardiovascular risk factors; 5292 untreated hypertensive patients referred to a single blood pressure clinic who had clinic and ambulatory blood pressure measurement at baseline were followed up in a prospective study of mortality outcome. Multiple Cox regression was used to model time to total and cause-specific mortality for ambulatory blood pressure measurement while adjusting for clinic blood pressure measurement and other risk factors at baseline. There were 646 deaths (of which 389 were cardiovascular) during a median follow-up period of 8. Key Words: blood pressure Ⅲ blood pressure monitoring, ambulatory Ⅲ cardiovascular diseases Ⅲ hypertension Ⅲ mortality T he most commonly used technique of blood pressure measurement in clinical practice is the auscultatory method with a mercury sphygmomanometer and stethoscope. A metaanalysis of clinic blood pressure measurement (CBPM) in 1 million adults participating in 61 prospective studies showed that a 10-mm Hg higher usual systolic blood pressure (SBP) or 5-mm Hg higher usual diastolic blood pressure (DBP) would be associated with Ϸ40% higher risk of stroke death and Ϸ30% higher risk of death from ischemic heart disease and other vascular causes. 1 There are, however, numerous criticisms of CBPM, which include interobserver and intraobserver variability, and terminal digit preferences, 2,3 all of which may bias the accuracy of measurement. Moreover, CBPM cannot detect white-coat hypertension, the prevalence of which can be as high as 30%. 4 There is growing evidence from a number of small studies that ambulatory blood pressure measurement (ABPM) is a better predictor of outcome than CBPM, 5-13 but only one large Japanese population study has shown ABPM to be better predictor of cardiovascular mortality than CBPM. 8 Similarly, evidence is accumulating to demonstrate that nighttime pressure is superior to daytime pressure in predicting cardiovascular outcome. 7,14 -21 The objective of this study, therefore, was to determine the additional predictive value of ABPM over and above CBPM, and also to estimate the superiority of nighttime pressure over daytime pressure in a large Western population of untreated hypertensive patients from a single center followed-up for up to 20 years.
T he most commonly used technique of blood pressure measurement in clinical practice is the auscultatory method with a mercury sphygmomanometer and stethoscope. A metaanalysis of clinic blood pressure measurement (CBPM) in 1 million adults participating in 61 prospective studies showed that a 10-mm Hg higher usual systolic blood pressure (SBP) or 5-mm Hg higher usual diastolic blood pressure (DBP) would be associated with Ϸ40% higher risk of stroke death and Ϸ30% higher risk of death from ischemic heart disease and other vascular causes. 1 There are, however, numerous criticisms of CBPM, which include interobserver and intraobserver variability, and terminal digit preferences, 2,3 all of which may bias the accuracy of measurement. Moreover, CBPM cannot detect white-coat hypertension, the prevalence of which can be as high as 30%. 4 There is growing evidence from a number of small studies that ambulatory blood pressure measurement (ABPM) is a better predictor of outcome than CBPM, [5] [6] [7] [8] [9] [10] [11] [12] [13] but only one large Japanese population study has shown ABPM to be better predictor of cardiovascular mortality than CBPM. 8 Similarly, evidence is accumulating to demonstrate that nighttime pressure is superior to daytime pressure in predicting cardiovascular outcome. 7,14 -21 The objective of this study, therefore, was to determine the additional predictive value of ABPM over and above CBPM, and also to estimate the superiority of nighttime pressure over daytime pressure in a large Western population of untreated hypertensive patients from a single center followed-up for up to 20 years.
Unit by their family doctors because of an elevated CBPM; 14 414 such patients were entered into a database during the study period (June 1, 1980 to September 30, 2002) . To be eligible for inclusion in the present report, patients had to be either untreated at baseline or to have had all antihypertensive drugs discontinued for 1 week before their baseline visit to the unit; demographic details and cardiovascular risk factors (sex, age, body mass index, smoking status, presence of diabetes mellitus, and history of previous cardiovascular events) had to be recorded; and the ABPM record had to include at least 10 daytime and 5 nighttime readings. Because of insufficient ABPM measurements, 201 patients were excluded. The total number of participants fulfilling the entry criteria on September 30, 2002 was 5292. The Hospital Ethics Committee approved the study.
Clinic Blood Pressure Measurement
A nurse measured blood pressure in the nondominant arm after 5 minutes of quiet sitting in accordance with contemporary recommendations 22, 23 using either a standard mercury sphygmomanometer or a calibrated and validated automated sphygmomanometer-the Omron HEM-705CP. 24 CBPM was calculated as the mean of 3 measurements.
Ambulatory Blood Pressure Measurement
ABPM measurements were made every half-hour throughout the 24-hour period using SpaceLabs 90202 and 90207 monitors (SpaceLabs Inc, Wokingham, Berkshire, UK), both of which have been previously shown to be accurate. 25, 26 All data were transferred into a software package (dabl Cardiovascular; Dabl Limited), 27 which allows calculation of SBP and DBP for the daytime period (average of readings between 0900 and 2100 hours), the nighttime period (average of readings between 0100 and 0600 hours), and the 24-hour period without applying any editing criteria. 28, 29 ABPM measurements were time-weighted. Hypertension was defined as a mean daytime ABPM of Ն135 mm Hg systolic or 85 mm Hg diastolic. 30 
Mortality Outcome
In the absence of a unique identifier to permit ready identification of subjects on the death register, mortality outcome was ascertained by searching a national computerized register of deaths for each individual whose name appeared in the dabl blood pressure database. This process was completed in a number of stages, which have been described previously. 31 Briefly, the register was first searched for patients having both similar names and approximate date of birth, so as to allow for different versions of first and surnames and/or misspelling in the death certificate, and also to overcome the omission of the actual date of birth by allowing a 2-year margin of error. If there was no match using these 2 criteria, the individual was considered to be alive. Where there was a positive match, the relevant death certificate was examined, and further confirmation of death was sought by checking addresses, hospital records, and family doctors records. This process provided definite evidence that 646 people from the 5292 individuals in the study cohort had died by September 30, 2002 . Because Irish death certificates state the cause of death but are not coded, the death certificate of each individual was examined and the cause of death was coded according to the World Health Organization's International Classification of Diseases, 9th Revision (ICD-9). 32 Cardiac mortality included myocardial infarction (ICD-9, 4100 to 4109), heart failure (4280 to 4289), sudden death (7980 to 7989), and chronic coronary heart disease (4140 to 4149). Cardiovascular mortality consisted of cardiac mortality, stroke (4300 to 4389), and other vascular deaths.
Statistical Analysis
The analyses were performed using SAS software, version 9 (SAS Institute Inc, Cary, NC). We compared means and proportions by the large sample z-test and the 2 statistic, respectively. We divided the distributions of the baseline blood pressure into quintiles. From one overall logistic regression model adjusted for gender and age, we computed the risk of an adverse outcome in each blood-pressure quintile relative to the common risk in all patients. We plotted these 5 risk estimates with 95% confidence intervals (CIs) against the average blood pressure in each quintile. 33 This analysis was performed on ambulatory SBP and DBP to test the hypothesis that ABPM predicts cardiovascular mortality. We then introduced CBPM and ABPM, or daytime and nighttime ABPM, as continuous variables in Cox proportional hazards regression. Relative hazard ratios and 95% CIs were calculated for each 10-mm Hg and 5-mm Hg increase in SBP and DBP, respectively. Adjustments were made for gender, age, body mass index, presence of diabetes mellitus, history of cardiovascular events, and current smoking status, along with further adjustment for CBPM.
Results

Baseline Characteristics
The characteristics of the patient populations are shown in Table 1 . Mean follow-up was 7.9 years (interquartile range, 5.6 years to 10.6 years). Ages at baseline ranged from 16.2 years to 92.4 years. There were 646 deaths, of which 389 were cardiovascular. The prevalence of known cardiovascular risk factors was higher among patients who died of cardiovascular causes.
Clinic and Ambulatory Blood Pressures as Predictors of Mortality Risk
Using a nonparametric approach with adjustment for gender and age, patients in the highest quintile for nighttime pressures were at higher relative risk compared with the overall group (Figure 1) . Patients in the highest quintile for nighttime SBP had a relative risk of a cardiovascular death of 1.30 (95% CI, 1.17 to 1.45; PϽ0.001). Table 2 shows the relative hazard ratios for 10-and 5-mm Hg increases in SBP and DBP, respectively, before and after adjustment for CBPM. With adjustments applied for baseline characteristics, the systolic ABPM predicted all mortality outcomes over and beyond systolic CBPM (PϽ0.001). Table 3 provides the fully adjusted Cox regression models for cardiovascular mortality and shows that the significance levels were considerably higher for the ambulatory than for the conventional blood pressure. ABPM was not forced into the models for any of the fatal outcome analyses. The hazard ratios associated with a 10-mm Hg increase in SBP were 1.12 (95% CI, 1.06 to 1.19; PϽ0.001), 1.21 (95% CI, 1.13 to 1.28; PϽ0.001), and 1.19 (95% CI, 1.13 to 1.27; PϽ0.001) for daytime, nighttime, and 24-hour ABPM, respectively. The corresponding adjusted relative hazard ratios associated with a 5-mm Hg increase in DBP were 1.03 (95% CI, 0.99 to 1.07; PϭNS), 1.07 (95% CI, 1.04 to 1.13; PϽ0.05), and 1.09 (95% CI, 1.02 to 1.11; PϽ0.01). Nighttime ABPM provides additional predictive information over daytime ABPM, as does ABPM SBP over ABPM DBP, for total, cardiovascular, stroke, and cardiac mortality (Table 4 ). Relative hazard ratios (95% confidence intervals) for each 10-mm Hg increase in systolic pressure and 5-mm Hg increase in diastolic pressure with adjustments applied for baseline characteristics including gender, age, body mass index, presence of diabetes mellitus, history of cardiovascular events, and smoking status, along with further adjustment for clinic blood pressure measurement.
Cardiac fatal endpoint includes heart failure, myocardial infarction, and sudden death. Significance of the hazard ratios: *PϽ0.05, †PϽ0.01, ‡PϽ0.001. Figure 2 demonstrates the absolute 5-year cardiovascular risk, after adjustment for other covariates, in relation to baseline ABPM and CBPM.
Discussion
To our knowledge, this single-center study is the largest to date to demonstrate that ABPM is a stronger predictor of cardiovascular mortality than CBPM, and that nighttime is superior to daytime ABPM in predicting cardiovascular mortality in a Western hypertensive population who were not using antihypertensive medication at the time of blood pressure measurement. A possible limitation to our study might have been the omission of deaths because of patients leaving the jurisdiction or changing names as a consequence of marriage. However, given the mean age of the patients, these occurrences are not likely to have been significant. We did not have sufficient data on antihypertensive medication during follow-up to adjust for the potential effect of treatment on outcome. The classic study by Perloff et al in 1983 was the first to demonstrate that ABPM was a better predictor of morbidity than CBPM in hypertensive patients. 5 Since then, a number of Model 3ϭdaytime SBP, daytime DBP, gender, age, body mass index, presence of diabetes mellitus, history of cardiovascular events, and current smoking status.
Model 4ϭnighttime SBP, nighttime DBP, gender, age, body mass index, presence of diabetes mellitus, history of cardiovascular events, and current smoking status.
Relative hazard ratios (95% confidence intervals) for each 10-mm Hg increase in systolic pressure and 5-mm Hg increase in diastolic pressure. Hazard ratios were also adjusted for baseline characteristics including gender, age, body mass index, presence of diabetes mellitus, history of cardiovascular events, and current smoking status.
Significance of the hazard ratios: *PϽ0.05, †PϽ0.01, ‡PϽ0.001. studies have confirmed that ABPM is a stronger predictor of outcome than CBPM. [5] [6] [7] [8] [9] [10] [11] [12] [13] A study in Spanish patients with refractory hypertension showed that patients with daytime ABPM in the lowest tertile (DBP Ͻ88 mm Hg) had a significantly lower rate of cardiovascular events over 4-year follow-up, irrespective of clinic pressures. 6 In 808 patients followed-up for 4.4 years in the placebo-controlled Syst-Eur trial, cardiovascular risk was Ͻ10% between the lowest and highest CBPMs, whereas the difference was Ϸ50% between the lowest and highest ABPM recordings. 7 A prospective Japanese study in 1542 patients showed that ABPM was a better predictor of mortality than screening blood pressure, 8 and a further analysis has shown that ABPM is also a stronger predictor of stroke. 9 In the Office versus Ambulatory blood pressure (OvA) study, both DBP and SBP ABPM predicted cardiovascular death in treated hypertensive patients after adjustment for CBPM. 10 The results of our single-center study in a large population confirm the superiority of ABPM over CBPM in predicting cardiovascular mortality. The dipper/nondipper classification of nocturnal blood pressure was first introduced in 1988 when a retrospective analysis suggested that nondipping hypertensive patients had a higher risk of stroke than the majority of patients with a dipping pattern. 14 Since then, there have been many studies evaluating morbidity and dipping status, and although there has been some disagreement in the literature, on balance, most large-scale prospective studies support the concept that a diminished nocturnal blood pressure decline is associated with a worse prognosis. 17, 18 Moreover, 3 longitudinal studies conducted in patients with hypertension have shown that a diminished nocturnal decline in blood pressure predicts cardiovascular events. 7, 19, 20 The first prospective study to demonstrate that a diminished nocturnal decline in blood pressure is a risk factor for cardiovascular mortality, independent of the overall blood pressure load during a 24-hour period, was the Ohasama study in a Japanese population, which showed that, on average, each 5% decrease in the decline in nocturnal blood pressure was associated with Ϸ20% greater risk of cardiovascular mortality. Importantly, this association was observed not only in hypertensive individuals but also in normotensive individuals. 21 The results of our study confirm that the important Japanese finding of a higher nocturnal blood pressure being a predictor of mortality is also true for a Western population. In our study, for each 10-mm Hg increase in mean nighttime SBP, the mortality risk increased by 21%.
The findings of our study have clinical relevance. Despite the abundance of evidence that ABPM is superior to CBPM, current guidelines generally recommend ABPM only for selected circumstances, such as the exclusion of white-coat hypertension. Our findings support the recommendation that ABPM is indispensable to the management of hypertension and that all patients with elevated CBPM should have an ABPM. 3 Moreover, the emerging importance of nocturnal blood pressure as an independent risk for cardiovascular outcome strengthens the call for 24-hour measurement of blood pressure. Future guidelines will have to address these issues.
Perspectives
This study has important clinical implications. First, we have shown in a large cohort of untreated hypertensive patients that increasing levels of CBPM provide only a modest increase in cardiovascular risk compared with nighttime or 24-hour ABPM. Second, because patients with elevated ABPM are at greater risk, irrespective of CBPM, the ready availability of ABPM in clinical practice would permit treatment to be targeted at the patients likely to benefit most. Third, the strong predictive value of nighttime blood pressure makes it important in clinical practice to direct more attention to nocturnal blood pressure, and this observation raises an interesting hypothesis for a prospective randomized clinical trial to show if treatment based on nighttime pressure will improve outcome. Using multiple Cox regression, the relative risk was calculated with adjustment for baseline characteristics including gender, age, presence of diabetes mellitus, history of cardiovascular events, and smoking status. The 5-year risks are expressed as number of deaths per 100 subjects.
